Gemma McCalmont
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gemma McCalmont has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Derk Frank
Department of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein , Campus Kiel, Kiel
2 shared publications - Douglas Muir
James Cook University Hospital, Middlesbrough, United Kingdom
2 shared publications - Eric Durand
Department of Cardiology, Université Rouen Normandie, Inserm U1096, CHU Rouen , Rouen
2 shared publications - Francesco Saia
Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna
2 shared publications - Sandra B. Lauck
University of British Columbia
2 shared publications Alexandra Audren
Department of Cardiology, University Rennes 1, CHU Rennes , Service de Cardiologie, Rennes
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (1)
The role of Clinical Valve Coordinators: a clinical consensus statement of the European Association of Percutaneous Cardiac Interventions and the Association of Cardiovascular Nursing & Allied Professions of the ESC
Background: Transcatheter options are increasingly available for the treatment of valvular heart disease. The role of the clinical valve co-ordinator is ideally positioned to improve access to care, quality of outcomes, and patient experiences, contribute to efficiencies, and support the growing number of heart valve centres. International societies and guidelines recommend the inclusion of the clinical valve co-ordinator in multidisciplinary Heart Teams to support patients, contribute unique expertise to team-based care, and help programmes expand access to care. The role of the clinical valve co-ordinator is unevenly adopted in Europe. Aims: To provide guidance on developing, implementing, and sustaining the role of clinical valve co-ordinators to support patients and programmes. Methods and results: We outline a comprehensive framework of the competencies and professional development aligned with the needs of patients with aortic, mitral, and tricuspid disease, discuss requirements for infrastructure and successful organizational integration in valvular heart disease teams and programmes, and propose preliminary indicators to measure role impact and address the current gap in evidence to guide role development across diverse regions. The clinical valve co-ordinator plays a vital role as a central member of the multidisciplinary team to support the care requirements of people with complex valvular heart disease in the rapidly evolving clinical context of treatment options and management strategies. Conclusion: The document provides a roadmap for the development, implementation, and evaluation of a pan-European initiative to improve the delivery of valvular heart disease services and optimize the experience of care of patients and their family.
- 1 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (1)
Open AccessThe role of Clinical Valve Coordinators: a clinical consensus statement of the European Association of Percutaneous Cardiac Interventions and the Association of Cardiovascular Nursing & Allied Professions of the ESC
Background: Transcatheter options are increasingly available for the treatment of valvular heart disease. The role of the clinical valve co-ordinator is ideally positioned to improve access to care, quality of outcomes, and patient experiences, contribute to efficiencies, and support the growing number of heart valve centres. International societies and guidelines recommend the inclusion of the clinical valve co-ordinator in multidisciplinary Heart Teams to support patients, contribute unique expertise to team-based care, and help programmes expand access to care. The role of the clinical valve co-ordinator is unevenly adopted in Europe. Aims: To provide guidance on developing, implementing, and sustaining the role of clinical valve co-ordinators to support patients and programmes. Methods and results: We outline a comprehensive framework of the competencies and professional development aligned with the needs of patients with aortic, mitral, and tricuspid disease, discuss requirements for infrastructure and successful organizational integration in valvular heart disease teams and programmes, and propose preliminary indicators to measure role impact and address the current gap in evidence to guide role development across diverse regions. The clinical valve co-ordinator plays a vital role as a central member of the multidisciplinary team to support the care requirements of people with complex valvular heart disease in the rapidly evolving clinical context of treatment options and management strategies. Conclusion: The document provides a roadmap for the development, implementation, and evaluation of a pan-European initiative to improve the delivery of valvular heart disease services and optimize the experience of care of patients and their family.
- Open Access
- 30 March 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (21) , 1904-1916
A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study
There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries. This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety. Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%). Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety. BENCHMARK: streamlined transcatheter aortic valve implantation (TAVI) pathway with retained safety. CCU, coronary care unit; ICU, intensive care unit; GW, general ward; IMC, intermediate care; PPM, permanent pacemaker. *Includes patients with available data on LoS only.
- 30 March 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (21) , 1904-1916
Open AccessA streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study
There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries. This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety. Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%). Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety. BENCHMARK: streamlined transcatheter aortic valve implantation (TAVI) pathway with retained safety. CCU, coronary care unit; ICU, intensive care unit; GW, general ward; IMC, intermediate care; PPM, permanent pacemaker. *Includes patients with available data on LoS only.